Drug Database · Clinicians

Caspofungin

Brands (14) Candina, Caspin, Fungitame 70…Show all

US brand (reference label): CANCIDAS; not a Philippine-registered brand.

Antimycotic for systemic use; Antifungal; and others PH FDA category

No kidney change; not dialyzableRx · Prescription drug17 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 3bad23a6-09a6-4194-9182-093ed61bc71c, version date October 11, 2024 (CANCIDAS · Merck Sharp & Dohme LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Empirical therapy for presumed fungal infections in febrile, neutropenic patients.
  • Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections.
  • Treatment of esophageal candidiasis.
  • Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE CANCIDAS is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. (1) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections.

(1) Treatment of esophageal candidiasis. (1) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. (1) 1.1 Empirical Therapy for Presumed Fungal Infections in Febrile, Neutropenic Patients CANCIDAS ® is indicated as empirical therapy for presumed fungal infections in febrile, neutropenic adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.1, 14.5)]. 1.2 Treatment of Candidemia and Other Candida Infections CANCIDAS is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.2, 14.5)].

Limitations of Use: CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida. 1.3 Treatment of Esophageal Candidiasis CANCIDAS is indicated for the treatment of esophageal candidiasis in adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.3, 14.5)]. Limitations of Use: CANCIDAS has not been approved for the treatment of oropharyngeal candidiasis (OPC).

In the study that evaluated the efficacy of caspofungin in the treatment of esophageal candidiasis, patients with concomitant OPC had higher relapse rate of the OPC [see Clinical Studies (14.3)]. 1.4 Treatment of Invasive Aspergillosis in Patients Who Are Refractory to or Intolerant of Other Therapies CANCIDAS is indicated for the treatment of invasive aspergillosis in adult and pediatric patients (3 months of age and older) who are refractory to or intolerant of other therapies [see Clinical Studies (14.4, 14.5)]. Limitations of Use: CANCIDAS has not been studied as initial therapy for invasive aspergillosis.

Contraindications

  • Hypersensitivity to caspofungin or any component
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS CANCIDAS is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to any component of this product [see Adverse Reactions (6)]. CANCIDAS is contraindicated in patients with known hypersensitivity to any component of this product. (4)

Dosing: Adult

  • Adults, most indications: 70 mg IV loading dose on day 1, then 50 mg once daily (infuse over about 1 hour)
  • Esophageal candidiasis: 50 mg once daily, no loading dose
  • Moderate hepatic impairment: 35 mg once daily (70 mg load where appropriate)
  • With rifampin: 70 mg once daily (consider with nevirapine, efavirenz, carbamazepine, dexamethasone, phenytoin)
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

Important Administration Instructions for All Patients (2.1): Administer by slow intravenous (IV) infusion over approximately 1 hour. Do not administer by IV bolus administration. Do not mix or co-infuse CANCIDAS with other medications. Do not use diluents containing dextrose (α–D-glucose). Dosage in Adults [18 years of age and older] (2.2): Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily for all indications except esophageal candidiasis.

For esophageal candidiasis, use 50 mg once daily with no loading dose. Dosage in Pediatric Patients [3 months to 17 years of age] (2.3): Dosing should be based on the patient's body surface area. For all indications, administer a single 70-mg/m 2 loading dose on Day 1, followed by 50 mg/m 2 once daily thereafter. Maximum loading dose and daily maintenance dose should not exceed 70 mg, regardless of the patient's calculated dose.

Dosage Adjustments in Patients with Hepatic Impairment (2.4): Reduce dosage for adult patients with moderate hepatic impairment (35 mg once daily, with a 70 mg loading dose on Day 1 where appropriate). Dosage Adjustment in Patients Receiving Concomitant Inducers of Hepatic CYP Enzymes (2.5): Use 70-mg once daily dose for adult patients on rifampin.

Consider dose increase to 70 mg once daily for adult patients on nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin. …

2.1 Important Administration Instructions for Use in All Patients

2.1 Important Administration Instructions for Use in All Patients Administer CANCIDAS by slow intravenous (IV) infusion over approximately 1 hour. Do not administer CANCIDAS by IV bolus administration.

2.2 Recommended Dosage in Adult Patients

2.2 Recommended Dosage in Adult Patients [18 years of age and older] The dosage and duration of CANCIDAS treatment for each indication are as follows: Empirical Therapy for Presumed Fungal Infections in Febrile Neutropenic Patients Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be based on the patient's clinical response.

Continue empirical therapy until resolution of neutropenia. In general, treat patients found to have a fungal infection for a minimum of 14 days after the last positive culture and continue treatment for at least 7 days after both neutropenia and clinical symptoms are resolved. If the 50-mg dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg.

Candidemia and Other Candida Infections Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be dictated by the patient's clinical and microbiological response. In general, continue antifungal therapy for at least 14 days after the last positive culture. Patients with neutropenia who remain persistently neutropenic may warrant a longer course of therapy pending resolution of the neutropenia.

Esophageal Candidiasis The dose is 50 mg once daily for 7 to 14 days after symptom resolution. A 70-mg loading dose has not been studied for this indication. Because of the risk of relapse of oropharyngeal candidiasis in patients with HIV infections, suppressive oral therapy could be considered [see Clinical Studies (14.3)].

Invasive Aspergillosis Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be based upon the severity of the patient's underlying disease, recovery from immunosuppression, and clinical response.

2.3 Recommended Dosing in Pediatric Patients

2.3 Recommended Dosing in Pediatric Patients [3 months to 17 years of age] For all indications, administer a single 70 mg/m 2 loading dose on Day 1, followed by 50 mg/m 2 once daily thereafter. The maximum loading dose and the daily maintenance dose should not exceed 70 mg, regardless of the patient's calculated dose. Dosing in pediatric patients (3 months to 17 years of age) should be based on the patient's body surface area (BSA) as calculated by the Mosteller Formula [see References (15)]: Following calculation of the patient's BSA, the loading dose in milligrams should be calculated as BSA (m 2) × 70 mg/m 2.

The maintenance dose in milligrams should be calculated as BSA (m 2) × 50 mg/m 2. Duration of treatment should be individualized to the indication, as described for each indication in adults [see Dosage and Administration (2.2)]. If the 50-mg/m 2 daily dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg/m 2 daily (not to exceed 70 mg).

Formula

2.4 Dosage Adjustments in Patients with Hepatic Impairment

2.4 Dosage Adjustments in Patients with Hepatic Impairment Adult patients with mild hepatic impairment (Child-Pugh score 5 to 6) do not need a dosage adjustment. For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), CANCIDAS 35 mg once daily is recommended based upon pharmacokinetic data [see Clinical Pharmacology (12.3)] with a 70-mg loading dose administered on Day 1 where appropriate.

There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) and in pediatric patients with any degree of hepatic impairment.

2.5 Dosage Adjustments in Patients Receiving Concomitant Inducers of Hepatic CYP Enzymes Adult

2.5 Dosage Adjustments in Patients Receiving Concomitant Inducers of Hepatic CYP Enzymes Adult Patients: Adult patients on rifampin should receive 70 mg of CANCIDAS once daily. When CANCIDAS is co-administered to adult patients with other inducers of hepatic CYP enzymes such as nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin, administration of a daily dose of 70 mg of CANCIDAS should be considered [see Drug Interactions (7)].

Pediatric Patients: Pediatric patients on rifampin should receive 70 mg/m 2 of CANCIDAS daily (not to exceed an actual daily dose of 70 mg). When CANCIDAS is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a CANCIDAS dose of 70 mg/m 2 once daily (not to exceed 70 mg) should be considered [see Drug Interactions (7)].

2.6 Preparation for Administration Reconstitution

2.6 Preparation for Administration Reconstitution of CANCIDAS for Intravenous Infusion Equilibrate the refrigerated vial of CANCIDAS to room temperature. Aseptically add 10.8 mL of 0.9% Sodium Chloride Injection, Sterile Water for Injection, Bacteriostatic Water for Injection with methylparaben and propylparaben, or Bacteriostatic Water for Injection with 0.9% benzyl alcohol to the vial.

Each vial of CANCIDAS contains an intentional overfill of CANCIDAS. Thus, the volume of diluent to be added to each vial and the drug concentration of the resulting solution is listed in Table 1 below. Table 1: Information for Preparation of CANCIDAS CANCIDAS vial (equivalent to caspofungin) Volume of diluent to be added Reconstitution volume of diluent to be added is based on the overfill amount of caspofungin (54.6 mg and 75.6 mg, respectively).

Resulting Concentration following Reconstitution 50 mg 10.8 mL 5 mg/mL 70 mg 10.8 mL 7 mg/mL The white to off-white cake will dissolve completely. Mix gently until a clear solution is obtained. Visually inspect the reconstituted solution for particulate matter or discoloration during reconstitution and prior to infusion.

Do not use if the solution is cloudy or has precipitated. The reconstituted solution of CANCIDAS in the vial may be stored for up to one hour at ≤25°C (≤77°F) prior to the preparation of the infusion solution in the intravenous bag or bottle. CANCIDAS vials are for single-dose only. Discard unused portion. Dilution of the Reconstituted Solution in the Intravenous Bag for Infusion Aseptically transfer the appropriate volume (mL) of reconstituted CANCIDAS to an intravenous (IV) bag (or bottle) containing 250 mL of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection.

Alternatively, the volume (mL) of reconstituted CANCIDAS can be added to a reduced volume of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/mL. This diluted infusion solution in the intravenous bag or bottle must be used within 24 hours if stored at ≤25°C (≤77°F) or within 48 hours if stored refrigerated at 2 to 8°C (36 to 46°F).

Important Reconstitution and Dilution Instructions for Pediatric Patients 3 Months of Age and Older Follow the reconstitution procedures described above using either the 70-mg or 50-mg vial to create the reconstituted solution [see Dosage and Administration (2.3)]. From the reconstituted solution in the vial, remove the volume of drug equal to the calculated loading dose or calculated maintenance dose based on a concentration of 7 mg/mL (if reconstituted from the 70-mg vial) or a concentration of 5 mg/mL (if reconstituted from the 50-mg vial).

The choice of vial should be based on total milligram dose of drug to be administered to the pediatric patient. To help ensure accurate dosing, it is recommended for pediatric doses less than 50 mg that 50-mg vials (with a concentration of 5 mg/mL) be used if available. The 70-mg vial should be reserved for pediatric patients requiring doses greater than 50 mg.

The maximum loading dose and the daily maintenance dose should not exceed 70 mg, regardless of the patient's calculated dose.

2.7 Drug Incompatibilities

2.7 Drug Incompatibilities Do not mix or co-infuse CANCIDAS with other medications, as there are no data available on the compatibility of CANCIDAS with other intravenous substances, additives, or medications. Do not use diluents containing dextrose (α-D-glucose), as CANCIDAS is not stable in diluents containing dextrose.

Dosing: Altered kidney function

Caspofungin is cleared by slow chemical degradation and hepatic uptake; only about 1.4% is excreted unchanged in urine. The US label needs no dose change in kidney impairment and no supplement after hemodialysis, which does not remove it. Moderate liver impairment and CYP inducers such as rifampin change the dose.

Kidney function measure: Label PK uses CrCl (mL/min); no dose bands.

Show full dosing details
CrCl ≥60 mL/min
No dose change (label).
CrCl 30–59 mL/min
No dose change (label). AUC rises 30% to 49% in moderate to end-stage kidney impairment after a single dose, without a dose change being needed (label).
CrCl 15–29 mL/min
No dose change (label). AUC rises 30% to 49% in moderate to end-stage kidney impairment after a single dose, without a dose change being needed (label).
CrCl <15 mL/min (not on dialysis)
No dose change (label). AUC rises 30% to 49% in moderate to end-stage kidney impairment after a single dose, without a dose change being needed (label).
Hemodialysis (intermittent)
No dose change; not dialyzable, so no supplement after hemodialysis (label).
Peritoneal dialysis
No peritoneal dialysis data in label; the label needs no change in kidney impairment. Specialist input.
CRRT
Not in label. Li 2020 (Table 3): no change in CVVH, CVVHD or CVVHDF.
  • Dialyzable? No (label). About 97% bound to albumin.
  • Monitoring Liver tests; potassium (low potassium is common); tacrolimus levels; liver enzymes with cyclosporine (label).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
No pediatric kidney dosing in label; adult label needs no change.
eGFR 30–59
No pediatric kidney dosing in label; adult label needs no change.
eGFR 15–29
No pediatric kidney dosing in label; adult label needs no change.
eGFR <15 (not on dialysis)
No pediatric kidney dosing in label; adult label needs no change.
Hemodialysis (intermittent)
No pediatric dialysis data. Specialist input.
Peritoneal dialysis
No pediatric dialysis data. Specialist input.
CRRT
No pediatric CRRT data in the cited sources. Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

8.7 Patients with Renal Impairment No dosage adjustment is necessary for patients with renal impairment. Caspofungin is not dialyzable; thus, supplementary dosing is not required following hemodialysis [see Clinical Pharmacology (12.3)].

Renal Impairment In a clinical study of single 70-mg doses, caspofungin pharmacokinetics were similar in healthy adult volunteers with mild renal impairment (creatinine clearance 50 to 80 mL/min) and control subjects. Moderate (creatinine clearance 31 to 49 mL/min), severe (creatinine clearance 5 to 30 mL/min), and end-stage (creatinine clearance less than 10 mL/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49% for AUC).

However, in adult patients with invasive aspergillosis, candidemia, or other Candida infections (intra-abdominal abscesses, peritonitis, or pleural space infections) who received multiple daily doses of CANCIDAS 50 mg, there was no significant effect of mild to end-stage renal impairment on caspofungin concentrations. No dosage adjustment is necessary for patients with renal impairment.

Caspofungin is not dialyzable, thus supplementary dosing is not required following hemodialysis.

Dosing: Hepatic impairment

8.6 Patients with Hepatic Impairment Adult patients with mild hepatic impairment (Child-Pugh score 5 to 6) do not need a dosage adjustment. For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), CANCIDAS 35 mg once daily is recommended based upon pharmacokinetic data [see Clinical Pharmacology (12.3)].

However, where recommended, a 70-mg loading dose should still be administered on Day 1 [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) and in pediatric patients 3 months to 17 years of age with any degree of hepatic impairment.

2.4 Dosage Adjustments in Patients with Hepatic Impairment Adult patients with mild hepatic impairment (Child-Pugh score 5 to 6) do not need a dosage adjustment. For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), CANCIDAS 35 mg once daily is recommended based upon pharmacokinetic data [see Clinical Pharmacology (12.3)] with a 70-mg loading dose administered on Day 1 where appropriate. There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) and in pediatric patients with any degree of hepatic impairment.

2.5 Dosage Adjustments in Patients Receiving Concomitant Inducers of Hepatic CYP Enzymes Adult Patients: Adult patients on rifampin should receive 70 mg of CANCIDAS once daily. When CANCIDAS is co-administered to adult patients with other inducers of hepatic CYP enzymes such as nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin, administration of a daily dose of 70 mg of CANCIDAS should be considered [see Drug Interactions (7)].

Pediatric Patients: Pediatric patients on rifampin should receive 70 mg/m 2 of CANCIDAS daily (not to exceed an actual daily dose of 70 mg). When CANCIDAS is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a CANCIDAS dose of 70 mg/m 2 once daily (not to exceed 70 mg) should be considered [see Drug Interactions (7)].

US FDA label

Dosing: Pediatric

Approved ages
3 months to 17 years (label).
Usual dose
70 mg/m2 loading dose on day 1, then 50 mg/m2 once daily (label).
Maximum dose
70 mg per dose (loading and daily) (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of CANCIDAS in pediatric patients 3 months to 17 years of age are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from prospective studies in pediatric patients 3 months to 17 years of age for the following indications [see Indications and Usage (1)]: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections.

Treatment of esophageal candidiasis. Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies (e.g., amphotericin B, lipid formulations of amphotericin B, itraconazole). The efficacy and safety of CANCIDAS has not been adequately studied in prospective clinical trials involving neonates and infants under 3 months of age.

Although limited pharmacokinetic data were collected in neonates and infants below 3 months of age, these data are insufficient to establish a safe and effective dose of caspofungin in the treatment of neonatal candidiasis. Invasive candidiasis in neonates has a higher rate of CNS and multi-organ involvement than in older patients; the ability of CANCIDAS to penetrate the blood-brain barrier and to treat patients with meningitis and endocarditis is unknown.

CANCIDAS has not been studied in pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida. CANCIDAS has also not been studied as initial therapy for invasive aspergillosis in pediatric patients. In clinical trials, 171 pediatric patients (0 months to 17 years of age), including 18 patients who were less than 3 months of age, were given intravenous CANCIDAS.

Pharmacokinetic studies enrolled a total of 66 pediatric patients, and an additional 105 pediatric patients received CANCIDAS in safety and efficacy studies [see Clinical Pharmacology (12.3) and Clinical Studies (14.5)]. The majority of the pediatric patients received CANCIDAS at a once-daily maintenance dose of 50 mg/m 2 for a mean duration of 12 days (median 9, range 1-87 days).

In all studies, safety was assessed by the investigator throughout study therapy and for 14 days following cessation of study therapy. The most common adverse reactions in pediatric patients treated with CANCIDAS were pyrexia (29%), blood potassium decreased (15%), diarrhea (14%), increased aspartate aminotransferase (12%), rash (12%), increased alanine aminotransferase (11%), hypotension (11%), and chills (11%) [see Adverse Reactions (6.2)].

Postmarketing hepatobiliary adverse reactions have been reported in pediatric patients with serious underlying medical conditions [see Warnings and Precautions (5.3)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical studies of CANCIDAS did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although the number of elderly patients was not large enough for a statistical analysis, no overall differences in safety or efficacy were observed between these and younger patients.

Plasma concentrations of caspofungin in healthy older men and women (65 years of age and older) were increased slightly (approximately 28% in AUC) compared to young healthy men. A similar effect of age on pharmacokinetics was seen in patients with candidemia or other Candida infections (intra-abdominal abscesses, peritonitis, or pleural space infections).

No dose adjustment is recommended for the elderly; however, greater sensitivity of some older individuals cannot be ruled out.

Administration

2.1 Important Administration Instructions for Use in All Patients Administer CANCIDAS by slow intravenous (IV) infusion over approximately 1 hour. Do not administer CANCIDAS by IV bolus administration.

2.6 Preparation for Administration Reconstitution of CANCIDAS for Intravenous Infusion Equilibrate the refrigerated vial of CANCIDAS to room temperature. Aseptically add 10.8 mL of 0.9% Sodium Chloride Injection, Sterile Water for Injection, Bacteriostatic Water for Injection with methylparaben and propylparaben, or Bacteriostatic Water for Injection with 0.9% benzyl alcohol to the vial. Each vial of CANCIDAS contains an intentional overfill of CANCIDAS. Thus, the volume of diluent to be added to each vial and the drug concentration of the resulting solution is listed in Table 1 below. Table 1: Information for Preparation of CANCIDAS CANCIDAS vial (equivalent to caspofungin) Volume of diluent to be added Reconstitution volume of diluent to be added is based on the overfill amount of caspofungin (54.6 mg and 75.6 mg, respectively). Resulting Concentration following Reconstitution 50 mg 10.8 mL 5 mg/mL 70 mg 10.8 mL 7 mg/mL The white to off-white cake will dissolve completely. Mix gently until a clear solution is obtained. Visually inspect the reconstituted solution for particulate matter or discoloration during reconstitution and prior to infusion. Do not use if the solution is cloudy or has precipitated. The reconstituted solution of CANCIDAS in the vial may be stored for up to one hour at ≤25°C (≤77°F) prior to the preparation of the infusion solution in the intravenous bag or bottle. CANCIDAS vials are for single-dose only. Discard unused portion. Dilution of the Reconstituted Solution in the Intravenous Bag for Infusion Aseptically transfer the appropriate volume (mL) of reconstituted CANCIDAS to an intravenous (IV) bag (or bottle) containing 250 mL of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection. Alternatively, the volume (mL) of reconstituted CANCIDAS can be added to a reduced volume of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/mL. This diluted infusion solution in the intravenous bag or bottle must be used within 24 hours if stored at ≤25°C (≤77°F) or within 48 hours if stored refrigerated at 2 to 8°C (36 to 46°F). Important Reconstitution and Dilution Instructions for Pediatric Patients 3 Months of Age and Older Follow the reconstitution procedures described above using either the 70-mg or 50-mg vial to create the reconstituted solution [see Dosage and Administration (2.3) ] . From the reconstituted solution in the vial, remove the volume of drug equal to the calculated loading dose or calculated maintenance dose based on a concentration of 7 mg/mL (if reconstituted from the 70-mg vial) or a concentration of 5 mg/mL (if reconstituted from the 50-mg vial). The choice of vial should be based on total milligram dose of drug to be administered to the pediatric patient. To help ensure accurate dosing, it is recommended for pediatric doses less than 50 mg that 50-mg vials (with a concentration of 5 mg/mL) be used if available. The 70-mg vial should be reserved for pediatric patients requiring doses greater than 50 mg. The maximum loading dose and the daily maintenance dose should not exceed 70 mg, regardless of the patient's calculated dose.

2.7 Drug Incompatibilities Do not mix or co-infuse CANCIDAS with other medications, as there are no data available on the compatibility of CANCIDAS with other intravenous substances, additives, or medications. Do not use diluents containing dextrose (α-D-glucose), as CANCIDAS is not stable in diluents containing dextrose.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for concentrate solution for iv infusion: 50 mg, 70 mg
  • Lyophilized powder for intravenous infusion: 50 mg, 70 mg
  • Lyophilized powder for concentrated solution for iv infusion: 70 mg
  • Lyophilized powder for injection for i.v. infusion: 50 mg, 70 mg
  • Lyophilized powder for iv infusion: 50 mg
  • Powder for concentrate for solution for iv infusion: 50 mg, 70 mg
  • Lyophilized powder for solution for infusion: 50 mg

Registered products in the Philippines

17 products registered with the Food and Drug Administration (FDA) Philippines list Caspofungin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products17
Philippine FDA-registered products for Caspofungin
Package insert
AscanexCaspofungin Acetate
50 mg Lyophilized Powder for Solution for InfusionUSP Type I Clear Glass Lyo Vial with 20 mm Bromobutyl Rubber Stopper & 20 mm Red Aluminum Flip-Off Seal x 10 mL (Box of 1's)
Rx
Gland Pharma LimitedIndia
Biocare Lifesciences, Inc.
DRP-10414
Sep 23, 2031
BDCaspo-50Caspofungin (as acetate)
50 mg Lyophilized Powder for Intravenous Infusion10 mL Clear USP Type I Glass Vial Box of 1’s
Rx
Sovereign Pharma Private LimitedIndia
Ambica International CorporationTrader: BDR Pharmaceuticals Pvt. Ltd.
DRP-5356
Sep 25, 2029
BDCaspo-70Caspofungin (as acetate)
70 mg Lyophilized Powder for Intravenous Infusion10 mL Clear USP Type I Glass Vial (Box of 1’s)
Rx
Sovereign Pharma Private LimitedIndia
Ambica International CorporationTrader: BDR Pharmaceuticals Pvt. Ltd.
DRP-5355
Oct 16, 2029
Brufungin 50Caspofungin (as acetate)
50 mg Lyophilized Powder for IV InfusionType I Clear Glass Vial x 10 mL with bromobutyl rubber stopper and blue flip-off seal (Box of 1's)
Rx
Brawn Laboratories Ltd.India
Bliss Pharma Distribution and Consultancy Corp.Importer: Bliss Pharma Distribution and Consultancy
DRP-14258
Aug 7, 2028
CandinaCaspofungin (as acetate)
50 mg Lyophilized Powder for Concentrate Solution for IV Infusion10 mL capacity Type I glass vial with grey butyl rubber stopper and an aluminum seal with red plastic flip-off cap (Box of 1's)
Rx
Gland Pharma LimitedIndia
The Cathay Drug Co., Inc.Trader: Galenicum Health S.L.
DR-XY46896
Oct 20, 2030
CandinaCaspofungin (as acetate)
70 mg Lyophilized Powder for Concentrate Solution for IV Infusion10 mL-capacity Type I glass vial with grey butyl rubber stopper and aluminum seal with orange plastic flip off cap (Box of 1's)
Rx
Gland Pharma LimitedIndia
The Cathay Drug Co., Inc.Trader: Galenicum Health S.L.
DR-XY47095
Oct 22, 2030
CapoginCaspofungin (as acetate)
50 mg Lyophilized Powder for Concentrate Solution for IV InfusionUSP Type I glass vial x 10 mL (net content) with grey bromobutyl rubber stopper and aluminum seal and blue flip-off cap (Box of 1’s)
Rx
Stanex Drugs & Chemicals Pvt. Ltd.India
One Dexcel Pharma, Inc.
DRP-18311
Jun 17, 2032
CasmygCaspofungin (as Acetate)
50 mg Lyophilized Powder for Intravenous Infusion10mL-capacity Type I glass vial with butyl rubber stopper and aluminum band with plastic flip-off cap (Box of 1's)
Rx
Pharmathen S.A.Greece
Saifen Drugs Philippines Inc.
DR-XY49456
Jul 30, 2030
CaspinCaspofungin (as acetate)
50mg Powder for Concentrate for Solution for IV Infusion10mL-capacity Type I Borosilicate Glass Vial with grey bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's)
Rx
Jiangsu Hengrui Medicine Co., Ltd.China
Phil Pharmawealth, Inc.
DR-XY47684
Jan 21, 2027
CaspinCaspofungin (as acetate)
70mg Powder for Concentrate for Solution for IV Infusion10mL-capacity Type I Borosilicate Glass Vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1's)
Rx
Jiangsu Henrui Medicine Co., LtdChina
Phil Pharmawealth, Inc.
DR-XY48866
Sep 5, 2028
Caspogrand 50Caspofungin (as Acetate)
50mg Lyophilized Powder for IV InfusionType 1 Clear Glass Vial x 10mL with Bromobutyl rubber stopper and blue flip-off seal (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Grandis Pharma IncorporatedImporter: Sbrg Exim Philippines Inc.
DRP-14258-01
Aug 7, 2028
Casponex 50Caspofungin (as acetate)
50 mg Lyophilized Powder for Concentrate Solution for Intravenous Infusion10 mL-capacity Ph. Eur. Type I clear and colorless glass vial with a bromobutyl rubber stopper and an aluminum seal with a red plastic flip-off cap (Box of 1's)
Rx
Hikma Italia S.p.A.Italy
BSV Bioscience Phils. Inc..Trader: Galenicum Health, S.L.U.
DR-XY49516
Sep 15, 2030
Casponex 70Caspofungin (as acetate)
70 mg Lyophilized Powder for Concentrate Solution for Intravenous Infusion10 mL-capacity Ph. Eur. Type I clear and colorless glass vial with a bromobutyl rubber stopper and an aluminum seal with an orange plastic flip-off cap (Box of 1's)
Rx
Hikma Italia S.p.A.Italy
BSV Bioscience Phils. Inc..Trader: Galenicum Health, S.L.U.
DR-XY49515
Sep 15, 2030
Fundaz-50Caspofungin (as acetate)
50 mg Lyophilized Powder for Injection for I.V. Infusion10 mL capacity USP Type I clearglass vial with 20 mm grey bromobutyl rubber stopper and 20 mm aluminum flip off seal (Box of 1's)
Rx
Indasi Lifescience Pvt. Ltd.India
Aglobal Care, Inc.
DRP-16021
Oct 17, 2029
Fundaz-70Caspofungin (as acetate)
70 mg Lyophilized Powder for Injection for I.V. Infusion10 mL Clear USP Type I Tubular Glass Vial 20mm slotted Gray Bromo butyl rubber stoppers (RFU) 20 mm Yellow Flip Off Seal (Box of 1's
Rx
Indasi Lifescience Pvt. Ltd.India
Aglobal Care, Inc.
DRP-15948
Oct 3, 2029
Fungitame 70Caspofungin (as acetate)
70 mg Lyophilized Powder for Concentrated Solution for IV InfusionType I Glass Vial Sealed with Rubber Stopper and Aluminum Band with Plastic Flip-Off Cap x 10 mL (Box of 1 Vial)
Rx
Pharmaten SAGreece
Saifen Drugs Philippines Inc.
DR-XY49086
May 20, 2029
Fungitame 70Caspofungin (as acetate)
70 mg Lyophilized Powder for Concentrated Solution for IV InfusionType I Glass Vial Sealed with Rubber Stopper and Aluminum Band with Plastic Flip-Off Cap x 10 mL (Box of 1 Vial)
Rx
Pharmathen SAGreece
Saifen Drugs Philippines Inc.
DRP-15622
May 20, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS CANCIDAS 50 mg is a white to off-white lyophilized cake or powder for reconstitution in a single-dose glass vial with a red aluminum band and a plastic cap. CANCIDAS 50-mg vial contains 50 mg of caspofungin equivalent to 55.5 mg of caspofungin acetate. CANCIDAS 70 mg is a white to off-white lyophilized cake or powder for reconstitution in a single-dose glass vial with a yellow/orange aluminum band and a plastic cap.

CANCIDAS 70-mg vial contains 70 mg of caspofungin equivalent to 77.7 mg of caspofungin acetate. For Injection: 50 or 70 mg lyophilized powder (plus allowance for overfill) in a single-dose vial for reconstitution (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity: Anaphylaxis, possible histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth or bronchospasm, and cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with use of CANCIDAS. Discontinue CANCIDAS at the first sign or symptom of a hypersensitivity reaction and administer appropriate treatment. (5.1)
  • Hepatic Effects: Can cause abnormalities in liver enzymes. Isolated cases of hepatic dysfunction, hepatitis, or hepatic failure have been reported. Monitor patients who develop abnormal liver enzymes for evidence of worsening hepatic function, and evaluate risk/benefit of continuing CANCIDAS. (5.2)
  • Elevated Liver Enzymes During Concomitant Use with Cyclosporine: Limit use to patients for whom potential benefit outweighs potential risk. Monitor patients who develop abnormal liver function tests (LFTs) during concomitant use with CANCIDAS. (5.3)
5.1 Hypersensitivity

5.1 Hypersensitivity Anaphylaxis and other hypersensitivity reactions have been reported during administration of CANCIDAS. Possible histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth or bronchospasm have been reported. Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some with a fatal outcome, have been reported with use of CANCIDAS [see Adverse Reactions (6.2)].

Discontinue CANCIDAS at the first sign or symptom of a hypersensitivity reaction and administer appropriate treatment.

5.2 Hepatic Effects

5.2 Hepatic Effects Laboratory abnormalities in liver function tests have been seen in healthy volunteers and in adult and pediatric patients treated with CANCIDAS. In some adult and pediatric patients with serious underlying conditions who were receiving multiple concomitant medications with CANCIDAS, isolated cases of clinically significant hepatic dysfunction, hepatitis, and hepatic failure have been reported; a causal relationship to CANCIDAS has not been established.

Monitor patients who develop abnormal liver function tests during CANCIDAS therapy for evidence of worsening hepatic function and evaluated for risk/benefit of continuing CANCIDAS therapy.

5.3 Elevated Liver Enzymes During Concomitant Use With Cyclosporine

5.3 Elevated Liver Enzymes During Concomitant Use With Cyclosporine Elevated liver enzymes have occurred in patients receiving CANCIDAS and cyclosporine concomitantly. Only use CANCIDAS and cyclosporine in those patients for whom the potential benefit outweighs the potential risk. Patients who develop abnormal liver enzymes during concomitant therapy should be monitored and the risk/benefit of continuing therapy should be evaluated.

Drug interactions

Drug or classSeverityEffectWhat to do
Rifampin and other CYP inducersAdjust or monitorLower caspofungin levels (label).Use 70 mg daily.
CyclosporineAdjust or monitorHigher caspofungin AUC; transient ALT/AST rises (label).Monitor liver enzymes.
TacrolimusAdjust or monitorLower tacrolimus levels (label).Monitor tacrolimus troughs; adjust.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Cyclosporine: In two adult clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of CANCIDAS. CANCIDAS did not increase the plasma levels of cyclosporine. There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered. Monitor patients who develop abnormal liver enzymes during concomitant therapy and evaluate the risk/benefit of continuing therapy [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

Tacrolimus: For patients receiving CANCIDAS and tacrolimus, standard monitoring of tacrolimus trough whole blood concentrations and appropriate tacrolimus dosage adjustments are recommended. Inducers of Hepatic CYP Enzymes Rifampin: Rifampin is a potent CYP3A4 inducer and concomitant administration with CANCIDAS is expected to reduce the plasma concentrations of CANCIDAS.

Therefore, adult patients on rifampin should receive 70 mg of CANCIDAS daily and pediatric patients on rifampin should receive 70 mg/m 2 of CANCIDAS daily (not to exceed an actual daily dose of 70 mg) [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. Other Inducers of Hepatic CYP Enzymes Adults: When CANCIDAS is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of CANCIDAS should be considered [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].

Pediatric Patients: When CANCIDAS is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg/m 2 CANCIDAS (not to exceed an actual daily dose of 70 mg) should be considered [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for CYP enzymes.

In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs.

Inducers of Hepatic CYP Enzymes Rifampin: Rifampin is a potent CYP3A4 inducer and concomitant administration with CANCIDAS is expected to reduce the plasma concentrations of CANCIDAS.

Adverse reactions

Common

  • Diarrhea, fever
  • Raised ALT, AST and alkaline phosphatase
  • Low potassium

Serious

  • Anaphylaxis; histamine-mediated reactions
  • Hepatic dysfunction
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following serious adverse reactions are discussed in detail in another section of the labeling: Hypersensitivity [see Warnings and Precautions (5.1)] Hepatic Effects [see Warnings and Precautions (5.2)] Elevated Liver Enzymes During Concomitant Use With Cyclosporine [see Warnings and Precautions (5.3)] Adults: Most common adverse reactions (incidence 10% or greater) are diarrhea, pyrexia, ALT/AST increased, blood alkaline phosphatase increased, and blood potassium decreased. (6.1)
  • Pediatric Patients: Most common adverse reactions (incidence ≥10%) are pyrexia, diarrhea, rash, ALT/AST increased, blood potassium decreased, hypotension, and chills. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of CANCIDAS cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Experience in Adults The overall safety of CANCIDAS was assessed in 1865 adult individuals who received single or multiple doses of CANCIDAS: 564 febrile, neutropenic patients (empirical therapy study); 382 patients with candidemia and/or intra-abdominal abscesses, peritonitis, or pleural space infections (including 4 patients with chronic disseminated candidiasis); 297 patients with esophageal and/or oropharyngeal candidiasis; 228 patients with invasive aspergillosis; and 394 individuals in phase I studies.

In the empirical therapy study patients had undergone hematopoietic stem-cell transplantation or chemotherapy. In the studies involving patients with documented Candida infections, the majority of the patients had serious underlying medical conditions (e.g., hematologic or other malignancy, recent major surgery, HIV) requiring multiple concomitant medications.

Patients in the noncomparative Aspergillus studies often had serious predisposing medical conditions (e.g., bone marrow or peripheral stem cell transplants, hematologic malignancy, solid tumors or organ transplants) requiring multiple concomitant medications. Empirical Therapy for Presumed Fungal Infections in Febrile Neutropenic Patients In the randomized, double-blinded empirical therapy study, patients received either CANCIDAS 50 mg/day (following a 70-mg loading dose) or AmBisome ® (amphotericin B liposome for injection, 3 mg/kg/day).

In this study clinical or laboratory hepatic adverse reactions were reported in 39% and 45% of patients in the CANCIDAS and AmBisome groups, respectively. Also reported was an isolated, serious adverse reaction of hyperbilirubinemia. Adverse reactions occurring in 7.5% or greater of the patients in either treatment group are presented in Table 2.

Table 2: Adverse Reactions Among Patients with Persistent Fever and Neutropenia Incidence 7.5% or greater for at Least One Treatment Group Adverse Reactions CANCIDAS 70 mg on Day 1, then 50 mg once daily for the remainder of treatment; daily dose was increased to 70 mg for 73 patients. N=564 (percent) AmBisome 3 mg/kg/day; daily dose was increased to 5 mg/kg for 74 patients.

N=547 (percent) Within any system organ class, individuals may experience more than 1 adverse reaction. All Systems, Any Adverse Reaction 95 97 Investigations 58 63 Alanine Aminotransferase Increased 18 20 Blood Alkaline Phosphatase Increased 15 23 Blood Potassium Decreased 15 23 Aspartate Aminotransferase Increased 14 17 Blood Bilirubin Increased 10 14 Blood Magnesium Decreased 7 9 Blood Glucose Increased 6 9 Bilirubin Conjugated Increased 5 9 Blood Urea Increased 4 8 Blood Creatinine Increased 3 11 General Disorders and Administration Site Conditions 57 63 Pyrexia 27 29 Chills 23 31 Edema Peripheral 11 12 Mucosal Inflammation 6 8 Gastrointestinal Disorders 50 55 Diarrhea 20 16 Nausea 11 20 Abdominal Pain 9 11 Vomiting 9 17 Respiratory, Thoracic and Mediastinal Disorders 47 49 Dyspnea 9 10 Skin and Subcutaneous Tissue Disorders 42 37 Rash 16 14 Nervous System Disorders 25 27 Headache 11 12 Metabolism and Nutrition Disorders 21 24 Hypokalemia 6 8 Vascular Disorders 20 23 Hypotension 6 10 Cardiac Disorders 16 19 Tachycardia 7 9 The proportion of patients who experienced an infusion-related adverse reaction (defined as a systemic event, such as pyrexia, chills, flushing, hypotension, hypertension, tachycardia, dyspnea, tachypnea, rash, or anaphylaxis, that developed during the study therapy infusion and one hour following infusion) was significantly lower in the group treated with CANCIDAS (35%) than in the group treated with AmBisome (52%).

To evaluate the effect of CANCIDAS and AmBisome on renal function, nephrotoxicity was defined as doubling of serum creatinine relative to baseline or an increase of greater than or equal to 1 mg/dL in serum creatinine if baseline serum creatinine was above the upper limit of the normal range. Among patients whose baseline creatinine clearance was greater than 30 mL/min, the incidence of nephrotoxicity was significantly lower in the group treated with CANCIDAS (3%) than in the group treated with AmBisome (12%).

Candidemia and Other Candida Infections In the randomized, double-blinded invasive candidiasis study, patients received either CANCIDAS 50 mg/day (following a 70-mg loading dose) or amphotericin B 0.6 to 1 mg/kg/day. Adverse reactions occurring in 10% or greater of the patients in either treatment group are presented in Table 3.

Table 3: Adverse Reactions Among Patients with Candidemia or Other Candida Infections Intra-abdominal abscesses, peritonitis and pleural space infections. Incidence 10% or Greater for at Least One Treatment Group Adverse Reactions CANCIDAS 50 mg Patients received CANCIDAS 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment.

N=114 (percent) Amphotericin B N=125 (percent) Within any system organ class, individuals may experience more than 1 adverse reaction. All Systems, Any Adverse Reaction 96 99 Investigations 67 82 Blood Potassium Decreased 23 32 Blood Alkaline Phosphatase Increased 21 32 Hemoglobin Decreased 18 23 Alanine Aminotransferase Increased 16 15 Aspartate Aminotransferase Increased 16 14 Blood Bilirubin Increased 13 17 Hematocrit Decreased 13 18 Blood Creatinine Increased 11 28 Red Blood Cells Urine Positive 10 10 Blood Urea Increased 9 23 Bilirubin Conjugated Increased 8 14 Gastrointestinal Disorders 49 53 Vomiting 17 16 Diarrhea 14 10 Nausea 9 17 General Disorders and Administration Site Conditions 47 63 Pyrexia 13 33 Edema Peripheral 11 12 Chills 9 30 Respiratory, Thoracic and Mediastinal Disorders 40 54 Tachypnea 1 11 Cardiac Disorders 26 34 Tachycardia 8 12 Skin and Subcutaneous Tissue Disorders 25 28 Rash 4 10 Vascular Disorders 25 38 Hypotension 10 16 Blood and Lymphatic System Disorders 15 13 Anemia 11 9 The proportion of patients who experienced an infusion-related adverse reaction (defined as a systemic event, such as pyrexia, chills, flushing, hypotension, hypertension, tachycardia, dyspnea, tachypnea, rash, or anaphylaxis, that developed during the study therapy infusion and one hour following infusion) was significantly lower in the group treated with CANCIDAS (20%) than in the group treated with amphotericin B (49%).

To evaluate the effect of CANCIDAS and amphotericin B on renal function, nephrotoxicity was defined as doubling of serum creatinine relative to baseline or an increase of greater than or equal to 1 mg/dL in serum creatinine if baseline serum creatinine was above the upper limit of the normal range. In a subgroup of patients whose baseline creatinine clearance was greater than 30 mL/min, the incidence of nephrotoxicity was significantly lower in the group treated with CANCIDAS than in the group treated with amphotericin B.

In a second randomized, double-blinded invasive candidiasis study, patients received either CANCIDAS 50 mg/day (following a 70-mg loading dose) or CANCIDAS 150 mg/day. The proportion of patients who experienced any adverse reaction was similar in the 2 treatment groups; however, this study was not large enough to detect differences in rare or unexpected adverse reactions.

Adverse reactions occurring in 5% or greater of the patients in either treatment group are presented in Table 4. Table 4: Adverse Reactions Among Patients with Candidemia or other Candida Infections Intra-abdominal abscesses, peritonitis and pleural space infections. Incidence 5% or Greater for at Least One Treatment Group Adverse Reactions CANCIDAS 50 mg Patients received CANCIDAS 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment.

N=104 (percent) CANCIDAS 150 mg N=100 (percent) Within any system organ class, individuals may experience more than 1 adverse event All Systems, Any Adverse Reaction 83 83 General Disorders and Administration Site Conditions 33 27 Pyrexia 6 6 Gastrointestinal Disorders 30 33 Vomiting 11 6 Diarrhea 6 7 Nausea 5 7 Investigations 28 35 Alkaline Phosphatase Increased 12 9 Aspartate Aminotransferase Increased 6 9 Blood potassium decreased 6 8 Alanine Aminotransferase Increased 4 7 Vascular Disorders 19 18 Hypotension 7 3 Hypertension 5 6 Esophageal Candidiasis and Oropharyngeal Candidiasis Adverse reactions occurring in 10% or greater of patients with esophageal and/or oropharyngeal candidiasis are presented in Table 5. Table 5: Adverse Reactions Among Patients with Esophageal and/or Oropharyngeal Candidiasis Incidence 10% or Greater for at Least One Treatment Group Adverse Reactions CANCIDAS 50 mg Derived from a comparator-controlled clinical study.

N=83 (percent) Fluconazole IV 200 mg N=94 (percent) Within any system organ class, individuals may experience more than 1 adverse reaction. All Systems, Any Adverse Reaction 90 93 Gastrointestinal Disorders 58 50 Diarrhea 27 18 Nausea 15 15 Investigations 53 61 Hemoglobin Decreased 21 16 Hematocrit Decreased 18 16 Aspartate Aminotransferase Increased 13 19 Blood Alkaline Phosphatase Increased 13 17 Alanine Aminotransferase Increased 12 17 White Blood Cell Count Decreased 12 19 General Disorders and Administration Site Conditions 31 36 Pyrexia 21 21 Vascular Disorders 19 15 Phlebitis 18 11 Nervous System Disorders 18 17 Headache 15 9 Invasive Aspergillosis In an open-label, noncomparative aspergillosis study, in which 69 patients received CANCIDAS (70-mg loading dose on Day 1 followed by 50 mg daily), the following adverse reactions were observed with an incidence of 12.5% or greater: blood alkaline phosphatase increased (22%), hypotension (20%), respiratory failure (20%), pyrexia (17%), diarrhea (15%), nausea (15%), headache (15%), rash (13%), alanine aminotransferase increased (13%), aspartate aminotransferase increased (13%), blood bilirubin increased (13%), and blood potassium decreased (13%).

Also reported in this patient population were pulmonary edema, ARDS (adult respiratory distress syndrome), and radiographic infiltrates. Clinical Trials Experience in Pediatric Patients (3 months to 17 years of age) The overall safety of CANCIDAS was assessed in 171 pediatric patients who received single or multiple doses of CANCIDAS.

The distribution among the 153 pediatric patients who were over the age of 3 months was as follows: 104 febrile, neutropenic patients; 38 patients with candidemia and/or intra-abdominal abscesses, peritonitis, or pleural space infections; 1 patient with esophageal candidiasis; and 10 patients with invasive aspergillosis. The overall safety profile of CANCIDAS in pediatric patients is comparable to that in adult patients.

Table 6 shows the incidence of adverse reactions reported in 7.5% or greater of pediatric patients in clinical studies. One patient (0.6%) receiving CANCIDAS, and three patients (12%) receiving AmBisome developed a serious drug-related adverse reaction. Two patients (1%) were discontinued from CANCIDAS and three patients (12%) were discontinued from AmBisome due to a drug-related adverse reaction.

The proportion of patients who experienced an infusion-related adverse reaction (defined as a systemic event, such as pyrexia, chills, flushing, hypotension, hypertension, tachycardia, dyspnea, tachypnea, rash, or anaphylaxis, that developed during the study therapy infusion and one hour following infusion) was 22% in the group treated with CANCIDAS and 35% in the group treated with AmBisome. Table 6: Adverse Reactions Among Pediatric Patients (0 months to 17 years of age) Incidence 7.5% or Greater for at Least One Treatment Group Noncomparative Clinical Studies Comparator-Controlled Clinical Study of Empirical Therapy Adverse Reactions CANCIDAS Any Dose N=115 (percent) CANCIDAS 50 mg/m 2 70 mg/m 2 on Day 1, then 50 mg/m 2 once daily for the remainder of the treatment.

N=56 (percent) AmBisome 3 mg/kg N=26 (percent) Within any system organ class, individuals may experience more than 1 adverse reaction. All Systems, Any Adverse Reaction 95 96 89 Investigations 55 41 50 Blood Potassium Decreased 18 9 27 Aspartate Aminotransferase Increased 17 2 12 Alanine Aminotransferase Increased 14 5 12 Blood Potassium Increased 3 0 8 General Disorders and Administration Site Conditions 47 59 42 Pyrexia 29 30 23 Chills 10 13 8 Mucosal Inflammation 10 4 4 Edema 3 4 8 Gastrointestinal Disorders 42 41 35 Diarrhea 17 7 15 Vomiting 8 11 12 Abdominal Pain 7 4 12 Nausea 4 4 8 Infections and Infestations 40 30 35 Central Line Infection 1 9 0 Skin and Subcutaneous Tissue Disorders 33 41 39 Pruritus 7 6 8 Rash 6 23 8 Erythema 4 9 0 Vascular Disorders 24 21 19 Hypotension 12 9 8 Hypertension 10 9 4 Metabolism and Nutrition Disorders 22 11 23 Hypokalemia 8 5 4 Cardiac Disorders 17 13 19 Tachycardia 4 11 19 Nervous System Disorders 13 16 8 Headache 5 9 4 Musculoskeletal and Connective Tissue Disorders 11 14 12 Back Pain 4 0 8 Blood and Lymphatic System Disorders 10 2 15 Anemia 2 0 8 Overall Safety Experience of CANCIDAS in Clinical Trials The overall safety of CANCIDAS was assessed in 2036 individuals (including 1642 adult or pediatric patients and 394 volunteers) from 34 clinical studies.

These individuals received single or multiple (once daily) doses of CANCIDAS, ranging from 5 mg to 210 mg. Full safety data is available from 1951 individuals, as the safety data from 85 patients enrolled in 2 compassionate use studies was limited solely to serious adverse reactions. Adverse reactions which occurred in 5% or greater of all individuals who received CANCIDAS in these trials are shown in Table 7.

Overall, 1665 of the 1951 (85%) patients/volunteers who received CANCIDAS experienced an adverse reaction. Table 7: Adverse Reactions Defined as an adverse reaction, regardless of causality, while on CANCIDAS or during the 14-day post-CANCIDAS follow-up period. in Patients Who Received CANCIDAS in Clinical Trials Incidence for each preferred term is 5% or greater among individuals who received at least 1 dose of CANCIDAS.

Incidence 5% or Greater for at Least One Treatment Group Adverse Reactions Within any system organ class, individuals may experience more than 1 adverse event. CANCIDAS (N = 1951) n (%) All Systems, Any Adverse Reaction 1665 (85) Investigations 901 (46) Alanine Aminotransferase Increased 258 (13) Aspartate Aminotransferase Increased 233 (12) Blood Alkaline Phosphatase Increased 232 (12) Blood Potassium Decreased 220 (11) Blood Bilirubin Increased 117 (6) General Disorders and Administration Site Conditions 843 (43) Pyrexia 381 (20) Chills 192 (10) Edema Peripheral 110 (6) Gastrointestinal Disorders 754 (39) Diarrhea 273 (14) Nausea 166 (9) Vomiting 146 (8) Abdominal Pain 112 (6) Infections and Infestations 730 (37) Pneumonia 115 (6) Respiratory, Thoracic, and Mediastinal Disorders 613 (31) Cough 111 (6) Skin and Subcutaneous Tissue Disorders 520 (27) Rash 159 (8) Erythema 98 (5) Nervous System Disorders 412 (21) Headache 193 (10) Vascular Disorders 344 (18) Hypotension 118 (6) Clinically significant adverse reactions, regardless of causality or incidence which occurred in less than 5% of patients are listed below.

Blood and lymphatic system disorders: anemia, coagulopathy, febrile neutropenia, neutropenia, thrombocytopenia Cardiac disorders: arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, myocardial infarction, tachycardia Gastrointestinal disorders: abdominal distension, abdominal pain upper, constipation, dyspepsia General disorders and administration site conditions: asthenia, fatigue, infusion site pain/pruritus/swelling, mucosal inflammation, edema Hepatobiliary disorders: hepatic failure, hepatomegaly, hepatotoxicity, hyperbilirubinemia, jaundice Infections and infestations: bacteremia, sepsis, urinary tract infection Metabolic and nutrition disorders: anorexia, decreased appetite, fluid overload, hypomagnesemia, hypercalcemia, hyperglycemia, hypokalemia Musculoskeletal, connective tissue, and bone disorders: arthralgia, back pain, pain in extremity Nervous system disorders: convulsion, dizziness, somnolence, tremor Psychiatric disorders: anxiety, confusional state, depression, insomnia Renal and urinary disorders: hematuria, renal failure Respiratory, thoracic, and mediastinal disorders: dyspnea, epistaxis, hypoxia, tachypnea Skin and subcutaneous tissue disorders: erythema, petechiae, skin lesion, urticaria Vascular disorders: flushing, hypertension, phlebitis

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following additional adverse reactions have been identified during the post-approval use of CANCIDAS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal disorders: pancreatitis Hepatobiliary disorders: hepatic necrosis Skin and subcutaneous tissue disorders: erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome, and skin exfoliation Renal and urinary disorders: clinically significant renal dysfunction General disorders and administration site conditions: swelling and peripheral edema Laboratory abnormalities: gamma-glutamyltransferase increased

Adverse reaction frequency tables (US label) US FDA label
Table 2: Adverse Reactions Among Patients with Persistent Fever and Neutropenia Incidence 7.5% or greater for at Least One Treatment Group
Adverse Reactions CANCIDAS70 mg on Day 1, then 50 mg once daily for the remainder of treatment; daily dose was increased to 70 mg for 73 patients. N=564 (percent) AmBisome3 mg/kg/day; daily dose was increased to 5 mg/kg for 74 patients. N=547 (percent)
Within any system organ class, individuals may experience more than 1 adverse reaction.
All Systems, Any Adverse Reaction 95 97
Investigations 58 63
Alanine Aminotransferase Increased 18 20
Blood Alkaline Phosphatase Increased 15 23
Blood Potassium Decreased 15 23
Aspartate Aminotransferase Increased 14 17
Blood Bilirubin Increased 10 14
Blood Magnesium Decreased 7 9
Blood Glucose Increased 6 9
Bilirubin Conjugated Increased 5 9
Blood Urea Increased 4 8
Blood Creatinine Increased 3 11
General Disorders and Administration Site Conditions 57 63
Pyrexia 27 29
Chills 23 31
Edema Peripheral 11 12
Mucosal Inflammation 6 8
Gastrointestinal Disorders 50 55
Diarrhea 20 16
Nausea 11 20
Abdominal Pain 9 11
Vomiting 9 17
Respiratory, Thoracic and Mediastinal Disorders 47 49
Dyspnea 9 10
Skin and Subcutaneous Tissue Disorders 42 37
Rash 16 14
Nervous System Disorders 25 27
Headache 11 12
Metabolism and Nutrition Disorders 21 24
Hypokalemia 6 8
Vascular Disorders 20 23
Hypotension 6 10
Cardiac Disorders 16 19
Tachycardia 7 9
Table 3: Adverse Reactions Among Patients with Candidemia or Other Candida InfectionsIntra-abdominal abscesses, peritonitis and pleural space infections. Incidence 10% or Greater for at Least One Treatment Group
Adverse Reactions CANCIDAS 50 mgPatients received CANCIDAS 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment. N=114 (percent) Amphotericin B N=125 (percent)
Within any system organ class, individuals may experience more than 1 adverse reaction.
All Systems, Any Adverse Reaction 96 99
Investigations 67 82
Blood Potassium Decreased 23 32
Blood Alkaline Phosphatase Increased 21 32
Hemoglobin Decreased 18 23
Alanine Aminotransferase Increased 16 15
Aspartate Aminotransferase Increased 16 14
Blood Bilirubin Increased 13 17
Hematocrit Decreased 13 18
Blood Creatinine Increased 11 28
Red Blood Cells Urine Positive 10 10
Blood Urea Increased 9 23
Bilirubin Conjugated Increased 8 14
Gastrointestinal Disorders 49 53
Vomiting 17 16
Diarrhea 14 10
Nausea 9 17
General Disorders and Administration Site Conditions 47 63
Pyrexia 13 33
Edema Peripheral 11 12
Chills 9 30
Respiratory, Thoracic and Mediastinal Disorders 40 54
Tachypnea 1 11
Cardiac Disorders 26 34
Tachycardia 8 12
Skin and Subcutaneous Tissue Disorders 25 28
Rash 4 10
Vascular Disorders 25 38
Hypotension 10 16
Blood and Lymphatic System Disorders 15 13
Anemia 11 9
Table 4: Adverse Reactions Among Patients with Candidemia or other Candida InfectionsIntra-abdominal abscesses, peritonitis and pleural space infections. Incidence 5% or Greater for at Least One Treatment Group
Adverse Reactions CANCIDAS 50 mgPatients received CANCIDAS 70 mg on Day 1, then 50 mg once daily for the remainder of their treatment. N=104 (percent) CANCIDAS 150 mg N=100 (percent)
Within any system organ class, individuals may experience more than 1 adverse event
All Systems, Any Adverse Reaction 83 83
General Disorders and Administration Site Conditions 33 27
Pyrexia 6 6
Gastrointestinal Disorders 30 33
Vomiting 11 6
Diarrhea 6 7
Nausea 5 7
Investigations 28 35
Alkaline Phosphatase Increased 12 9
Aspartate Aminotransferase Increased 6 9
Blood potassium decreased 6 8
Alanine Aminotransferase Increased 4 7
Vascular Disorders 19 18
Hypotension 7 3
Hypertension 5 6
Table 5: Adverse Reactions Among Patients with Esophageal and/or Oropharyngeal Candidiasis Incidence 10% or Greater for at Least One Treatment Group
Adverse Reactions CANCIDAS 50 mgDerived from a comparator-controlled clinical study. N=83 (percent) Fluconazole IV 200 mg N=94 (percent)
Within any system organ class, individuals may experience more than 1 adverse reaction.
All Systems, Any Adverse Reaction 90 93
Gastrointestinal Disorders 58 50
Diarrhea 27 18
Nausea 15 15
Investigations 53 61
Hemoglobin Decreased 21 16
Hematocrit Decreased 18 16
Aspartate Aminotransferase Increased 13 19
Blood Alkaline Phosphatase Increased 13 17
Alanine Aminotransferase Increased 12 17
White Blood Cell Count Decreased 12 19
General Disorders and Administration Site Conditions 31 36
Pyrexia 21 21
Vascular Disorders 19 15
Phlebitis 18 11
Nervous System Disorders 18 17
Headache 15 9
Table 6: Adverse Reactions Among Pediatric Patients (0 months to 17 years of age) Incidence 7.5% or Greater for at Least One Treatment Group
Noncomparative Clinical Studies Comparator-Controlled Clinical Study of Empirical Therapy
Adverse Reactions CANCIDAS Any Dose N=115 (percent) CANCIDAS 50 mg/m2 70 mg/m2 on Day 1, then 50 mg/m2 once daily for the remainder of the treatment. N=56 (percent) AmBisome 3 mg/kg N=26 (percent)
Within any system organ class, individuals may experience more than 1 adverse reaction.
All Systems, Any Adverse Reaction 95 96 89
Investigations 55 41 50
Blood Potassium Decreased 18 9 27
Aspartate Aminotransferase Increased 17 2 12
Alanine Aminotransferase Increased 14 5 12
Blood Potassium Increased 3 0 8
General Disorders and Administration Site Conditions 47 59 42
Pyrexia 29 30 23
Chills 10 13 8
Mucosal Inflammation 10 4 4
Edema 3 4 8
Gastrointestinal Disorders 42 41 35
Diarrhea 17 7 15
Vomiting 8 11 12
Abdominal Pain 7 4 12
Nausea 4 4 8
Infections and Infestations 40 30 35
Central Line Infection 1 9 0
Skin and Subcutaneous Tissue Disorders 33 41 39
Pruritus 7 6 8
Rash 6 23 8
Erythema 4 9 0
Vascular Disorders 24 21 19
Hypotension 12 9 8
Hypertension 10 9 4
Metabolism and Nutrition Disorders 22 11 23
Hypokalemia 8 5 4
Cardiac Disorders 17 13 19
Tachycardia 4 11 19
Nervous System Disorders 13 16 8
Headache 5 9 4
Musculoskeletal and Connective Tissue Disorders 11 14 12
Back Pain 4 0 8
Blood and Lymphatic System Disorders 10 2 15
Anemia 2 0 8
Table 7: Adverse ReactionsDefined as an adverse reaction, regardless of causality, while on CANCIDAS or during the 14-day post-CANCIDAS follow-up period. in Patients Who Received CANCIDAS in Clinical TrialsIncidence for each preferred term is 5% or greater among individuals who received at least 1 dose of CANCIDAS. Incidence 5% or Greater for at Least One Treatment Group
Adverse ReactionsWithin any system organ class, individuals may experience more than 1 adverse event. CANCIDAS (N = 1951)
n (%)
All Systems, Any Adverse Reaction 1665 (85)
Investigations 901 (46)
Alanine Aminotransferase Increased 258 (13)
Aspartate Aminotransferase Increased 233 (12)
Blood Alkaline Phosphatase Increased 232 (12)
Blood Potassium Decreased 220 (11)
Blood Bilirubin Increased 117 (6)
General Disorders and Administration Site Conditions 843 (43)
Pyrexia 381 (20)
Chills 192 (10)
Edema Peripheral 110 (6)
Gastrointestinal Disorders 754 (39)
Diarrhea 273 (14)
Nausea 166 (9)
Vomiting 146 (8)
Abdominal Pain 112 (6)
Infections and Infestations 730 (37)
Pneumonia 115 (6)
Respiratory, Thoracic, and Mediastinal Disorders 613 (31)
Cough 111 (6)
Skin and Subcutaneous Tissue Disorders 520 (27)
Rash 159 (8)
Erythema 98 (5)
Nervous System Disorders 412 (21)
Headache 193 (10)
Vascular Disorders 344 (18)
Hypotension 118 (6)

Monitoring parameters

  • Liver tests; potassium (low potassium is common); tacrolimus levels; liver enzymes with cyclosporine (label). Kidney
  • Liver tests
  • Potassium
  • Tacrolimus levels
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on animal data, CANCIDAS may cause fetal harm (see Data). There are insufficient human data to establish whether there is a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with CANCIDAS use in pregnant women. In animal studies, caspofungin caused embryofetal toxicity, including increased resorptions, increased peri-implantation loss, and incomplete ossification at multiple fetal sites when administered intravenously to pregnant rats and rabbits during organogenesis at doses up to 0.8 and 2 times the clinical dose, respectively (see Data).

Advise patients of the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data Animal Data In animal reproduction studies, pregnant rats dosed intravenously with caspofungin during organogenesis (gestational days [GD] 6 to 20) at 0.5, 2, or 5 mg/kg/day (up to 0.8 times the clinical dose based on body surface area comparison) showed increased resorptions and peri-implantation losses at 5 mg/kg/day. Incomplete ossification of the skull and torso and increased incidences of cervical rib were noted in offspring born to pregnant rats treated at doses up to 5 mg/kg/day.

In pregnant rabbits treated with intravenous caspofungin during organogenesis (GD 7 to 20) at doses of 1, 3, or 6 mg/kg/day (approximately 2 times the clinical dose based on body surface area comparison), increased fetal resorptions and increased incidence of incomplete ossification of the talus/calcaneus in offspring were observed at the highest dose tested. Caspofungin crossed the placenta in rats and rabbits and was detectable in fetal plasma.

In peri- and postnatal development study in rats, intravenous caspofungin administered at 0.5, 2 or 5 mg/kg/day from Day 6 of gestation through Day 20 of lactation was not associated with any adverse effects on reproductive performance or subsequent development of first generation (F1) offspring or malformations in second generation (F2) offspring.

Mechanism of action

12.1 Mechanism of Action Caspofungin is an echinocandin antifungal drug [see Microbiology (12.4)].

US FDA label

Pharmacokinetics

Key PK parameters

Half-lifeBeta phase 9 to 11 hours; gamma phase 40 to 50 hours
Half-life in kidney failure (ESKD) kidneyAUC up 30% to 49% (single dose; label)
Protein bindingAbout 97% (albumin)
Metabolism (CYP, transporters)Spontaneous degradation and hydrolysis/N-acetylation
Renal excretion kidneyAbout 1.4% unchanged in urine
Dialyzability kidneyNo (label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

A short α-phase occurs immediately postinfusion, followed by a β-phase (half-life of 9 to 11 hours) that characterizes much of the profile and exhibits clear log-linear behavior from 6 to 48 hours postdose during which the plasma concentration decreases 10-fold.

An additional, longer half-life phase, γ-phase, (half-life of 40-50 hours), also occurs.

Distribution, rather than excretion or biotransformation, is the dominant mechanism influencing plasma clearance.

There is little excretion or biotransformation of caspofungin during the first 30 hours after administration.

Excretion Two single-dose radiolabeled pharmacokinetic studies were conducted.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Adult and pediatric pharmacokinetic parameters are presented in Table 8. Distribution Plasma concentrations of caspofungin decline in a polyphasic manner following single 1-hour IV infusions. A short α-phase occurs immediately postinfusion, followed by a β-phase (half-life of 9 to 11 hours) that characterizes much of the profile and exhibits clear log-linear behavior from 6 to 48 hours postdose during which the plasma concentration decreases 10-fold.

An additional, longer half-life phase, γ-phase, (half-life of 40-50 hours), also occurs. Distribution, rather than excretion or biotransformation, is the dominant mechanism influencing plasma clearance. Caspofungin is extensively bound to albumin (~97%), and distribution into red blood cells is minimal. Mass balance results showed that approximately 92% of the administered radioactivity was distributed to tissues by 36 to 48 hours after a single 70-mg dose of [3 H] CANCIDAS.

There is little excretion or biotransformation of caspofungin during the first 30 hours after administration. Metabolism Caspofungin is slowly metabolized by hydrolysis and N-acetylation. Caspofungin also undergoes spontaneous chemical degradation to an open-ring peptide compound, L-747969. At later time points (≥5 days postdose), there is a low level (≤7 picomoles/mg protein, or ≤1.3% of administered dose) of covalent binding of radiolabel in plasma following single-dose administration of [3 H] CANCIDAS, which may be due to two reactive intermediates formed during the chemical degradation of caspofungin to L-747969.

Additional metabolism involves hydrolysis into constitutive amino acids and their degradates, including dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine. These two tyrosine derivatives are found only in urine, suggesting rapid clearance of these derivatives by the kidneys. Excretion Two single-dose radiolabeled pharmacokinetic studies were conducted.

In one study, plasma, urine, and feces were collected over 27 days, and in the second study plasma was collected over 6 months. Plasma concentrations of radioactivity and of caspofungin were similar during the first 24 to 48 hours postdose; thereafter drug levels fell more rapidly. In plasma, caspofungin concentrations fell below the limit of quantitation after 6 to 8 days postdose, while radiolabel fell below the limit of quantitation at 22.3 weeks postdose.

After single intravenous administration of [3 H] CANCIDAS, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine. A small amount of caspofungin is excreted unchanged in urine (~1.4% of dose). Renal clearance of parent drug is low (~0.15 mL/min) and total clearance of caspofungin is 12 mL/min.

Special Populations Renal Impairment In a clinical study of single 70-mg doses, caspofungin pharmacokinetics were similar in healthy adult volunteers with mild renal impairment (creatinine clearance 50 to 80 mL/min) and control subjects. Moderate (creatinine clearance 31 to 49 mL/min), severe (creatinine clearance 5 to 30 mL/min), and end-stage (creatinine clearance less than 10 mL/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49% for AUC).

However, in adult patients with invasive aspergillosis, candidemia, or other Candida infections (intra-abdominal abscesses, peritonitis, or pleural space infections) who received multiple daily doses of CANCIDAS 50 mg, there was no significant effect of mild to end-stage renal impairment on caspofungin concentrations. No dosage adjustment is necessary for patients with renal impairment.

Caspofungin is not dialyzable, thus supplementary dosing is not required following hemodialysis. Hepatic Impairment Plasma concentrations of caspofungin after a single 70-mg dose in adult patients with mild hepatic impairment (Child-Pugh score 5 to 6) were increased by approximately 55% in AUC compared to healthy control subjects.

In a 14-day multiple-dose study (70 mg on Day 1 followed by 50 mg daily thereafter), plasma concentrations in adult patients with mild hepatic impairment were increased modestly (19 to 25% in AUC) on Days 7 and 14 relative to healthy control subjects. No dosage adjustment is recommended for patients with mild hepatic impairment.

Adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9) who received a single 70-mg dose of CANCIDAS had an average plasma caspofungin increase of 76% in AUC compared to control subjects. A dosage reduction is recommended for adult patients with moderate hepatic impairment based upon these pharmacokinetic data [see Dosage and Administration (2.4)].

There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) or in pediatric patients with any degree of hepatic impairment. Gender Plasma concentrations of caspofungin in healthy adult men and women were similar following a single 70-mg dose. After 13 daily 50-mg doses, caspofungin plasma concentrations in women were elevated slightly (approximately 22% in area under the curve [AUC]) relative to men.

No dosage adjustment is necessary based on gender. Race Regression analyses of patient pharmacokinetic data indicated that no clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, and Hispanics. No dosage adjustment is necessary on the basis of race. Geriatric Patients Plasma concentrations of caspofungin in healthy older men and women (65 years of age and older) were increased slightly (approximately 28% AUC) compared to young healthy men after a single 70-mg dose of caspofungin.

In patients who were treated empirically or who had candidemia or other Candida infections (intra-abdominal abscesses, peritonitis, or pleural space infections), a similar modest effect of age was seen in older patients relative to younger patients. No dosage adjustment is necessary for the elderly [see Use in Specific Populations (8.5)].

Pediatric Patients CANCIDAS has been studied in five prospective studies involving pediatric patients under 18 years of age, including three pediatric pharmacokinetic studies [initial study in adolescents (12-17 years of age) and children (2-11 years of age) followed by a study in younger patients (3-23 months of age) and then followed by a study in neonates and infants (less than 3 months of age)] [see Use in Specific Populations (8.4)]. Pharmacokinetic parameters following multiple doses of CANCIDAS in pediatric and adult patients are presented in Table 8.

Table 8: Pharmacokinetic Parameters Following Multiple Doses of CANCIDAS in Pediatric (3 months to 17 years) and Adult Patients Population N Daily Dose Pharmacokinetic Parameters (Mean ± Standard Deviation) AUC 0-24hr (μg∙hr/mL) C 1hr (μg/mL) C 24hr (μg/mL) t 1/2 (hr) Harmonic Mean ± jackknife standard deviation CI (mL/min) PEDIATRIC PATIENTS Adolescents, Aged 12-17 years 8 50 mg/m 2 124.9 ± 50.4 14.0 ± 6.9 2.4 ± 1.0 11.2 ± 1.7 12.6 ± 5.5 Children, Aged 2-11 years 9 50 mg/m 2 120.0 ± 33.4 16.1 ± 4.2 1.7 ± 0.8 8.2 ± 2.4 6.4 ± 2.6 Young Children, Aged 3-23 months 8 50 mg/m 2 131.2 ± 17.7 17.6 ± 3.9 1.7 ± 0.7 8.8 ± 2.1 3.2 ± 0.4 ADULT PATIENTS Adults with Esophageal Candidiasis 6 N=5 for C 1hr and AUC 0-24hr; N=6 for C 24hr 50 mg 87.3 ± 30.0 8.7 ± 2.1 1.7 ± 0.7 13.0 ± 1.9 10.6 ± 3.8 Adults receiving Empirical Therapy 119 N=117 for C 24hr; N=119 for C 1hr 50 mg Following an initial 70-mg loading dose on day 1 -- 8.0 ± 3.4 1.6 ± 0.7 -- -- Drug Interactions [see Drug Interactions (7)] Studies in vitro show that caspofungin acetate is not an inhibitor of any enzyme in the cytochrome P (CYP) system. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for CYP enzymes.

In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs. Clinical studies in adult healthy volunteers also demonstrated that the pharmacokinetics of caspofungin are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus. Caspofungin has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.

Cyclosporine: In two adult clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%. CANCIDAS did not increase the plasma levels of cyclosporine. There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered [see Warnings and Precautions (5.2)].

Tacrolimus: CANCIDAS reduced the blood AUC 0-12 of tacrolimus (FK-506, Prograf ®) by approximately 20%, peak blood concentration (C max) by 16%, and 12-hour blood concentration (C 12hr) by 26% in healthy adult subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone. For patients receiving both therapies, standard monitoring of tacrolimus whole blood trough concentrations and appropriate tacrolimus dosage adjustments are recommended.

Rifampin: A drug-drug interaction study with rifampin in adult healthy volunteers has shown a 30% decrease in caspofungin trough concentrations [see Dosage and Administration (2.5)]. Other Inducers of Hepatic CYP Enzymes Adults: Results from regression analyses of adult patient pharmacokinetic data suggest that co-administration of other hepatic CYP enzyme inducers (e.g., efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.

It is not known which drug clearance mechanism involved in caspofungin disposition may be inducible [see Dosage and Administration (2.5)]. Pediatric patients: In pediatric patients, results from regression analyses of pharmacokinetic data suggest that co-administration of dexamethasone with CANCIDAS may result in clinically meaningful reductions in caspofungin trough concentrations.

This finding may indicate that pediatric patients will have similar reductions with inducers as seen in adults [see Dosage and Administration (2.5)].

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. CANCIDAS · Merck Sharp & Dohme LLC [US FDA-approved label, version 42, October 11, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Merck Sharp & Dohme LLC. (2024). CANCIDAS (caspofungin acetate) for injection [Prescribing information; US FDA-approved label, NDA021227, set ID 3bad23a6-09a6-4194-9182-093ed61bc71c, version effective October 11, 2024]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c
  4. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .